- 1 Repurposing chlorpromazine as add-on in the adjuvant phase of first-line
- 2 glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated
- 3 MGMT gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial
- 4 Andrea Pace<sup>1</sup>, Giuseppe Lombardi<sup>2</sup>, Veronica Villani<sup>1</sup>, Dario Benincasa<sup>1</sup>, Claudia Abbruzzese<sup>1</sup>,
- 5 Ilaria Cestonaro<sup>2</sup>, Martina Corrà<sup>2</sup>, Giulia Cerretti<sup>2</sup>, Mario Caccese<sup>2</sup>, Antonio Silvani<sup>3</sup>, Paola
- 6 Gaviani<sup>3</sup>, Diana Giannarelli<sup>4</sup> and Marco G. Paggi<sup>1\$</sup>
- 7 <sup>1</sup> IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 8 <sup>2</sup> Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
- 9 <sup>3</sup> IRCCS Besta Neurological Institute, Milan, Italy
- 10 <sup>4</sup> Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

## <sup>11</sup> <sup>\$</sup>Corresponding author:

- 12 Marco G. Paggi, MD, PhD
- 13 IRCCS Regina Elena National Cancer Institute
- 14 Via Elio Chianesi 53, 00144 Rome, Italy
- 15 Tel.: +39-06-5266.2550; Email: marco.paggi@ifo.it
- 16

## 17 Abstract

- 18 Background. Glioblastoma (GBM) is a devastating brain tumor with poor prognosis,
- 19 characterized by rapid growth and invasion into surrounding brain tissue. It is a hard-to-treat
- 20 cancer and represents an unmet medical need. In recent years, there has been a growing
- 21 interest in developing novel approaches to improve the outcomes of GBM patients; among
- 22 these, drug repurposing. Our preclinical studies identified the antipsychotic chlorpromazine
- 23 (CPZ) as an important modulator of signal transduction and energy metabolism in GBM cells,
- so we embarked on a Phase II clinical trial in which CPZ has been added to the standard
- 25 disease treatment.
- 26 **Methods**. With these assumptions, we started a multicenter phase II clinical trial on newly
- 27 diagnosed GBM patients carrying hypo-/un-methylated *MGMT* gene promoter by adding
- 28 CPZ to temozolomide (TMZ) in the adjuvant phase of the standard first-line therapeutic
- 29 protocol RACTAC schedule). Primary endpoints: Progression-Free Survival (PFS) and
- 30 Combination treatment toxicity. Secondary endpoints: Overall Survival (OS) and Quality of
- 31 Life (QoL)
- 32 **Results**. The RACTAC schedule showed an overall clinical benefit in GBM patients carrying
- 33 hypo-/un-methylated *MGMT* gene promoter. When compared with historical cohorts, these
- 34 patients displayed longer PFS, with toxicity described as a dose-dependent sedation and liver
- toxicity, both expected. One case of severe liver toxicity has been reported. OS and QoL are
- 36 still under evaluation.
- 37 **Conclusions**. This clinical trial confirms the anticancer properties of CPZ, as described in
- 38 several preclinical studies. In addition, the RACTAC study can be considered at least as a
- 39 proof-of-concept in demonstrating the effectiveness of interfering with the well-described
- 40 oncogenic monoamine signaling between neurons and GBM.
- 41
- 42 **Keywords**: Glioblastoma; Drug repurposing; Chlorpromazine; Phase II multicenter single-arm
- 43 clinical trial.
- 44

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 45 Introduction

46	Glioblastoma (GBM) is the most frequent and severe brain tumor, characterized by poor
47	response to treatment and an almost certainty of relapse. First-line GBM treatment,
48	regardless of the molecular classification of the disease <sup>1</sup> , consists in maximal surgical
49	resection followed by radiotherapy with concomitant temozolomide (TMZ) treatment,
50	followed by adjuvant TMZ administration. This scheme is however associated with a median
51	overall survival of 14.6 months and a 5-year survival <5% <sup>2</sup> , a clinical course that clearly
52	denotes an unmet medical need.
53	Given its peculiar biological characteristics, GBM presents high invasive and infiltrative
54	properties <sup>3</sup> , also coupled with a distinctive cellular heterogeneity, a prerequisite for a swift
55	adaptation under therapeutic pressure <sup>4-7</sup> . A key role in GBM resistance to therapy is played
56	by its ability to recover from genetic damages induced by radiotherapy and TMZ, by means
57	of an effective DNA repair, especially in tumors characterized by unmethylated O6-
58	methylguanine methyltransferase (MGMT) gene promoter <sup>8</sup> . Of note, GBM is among the few
59	tumors in which a single-drug treatment is currently in use, in contrast with most
60	therapeutic approaches in oncology and with its intratumor heterogeneity.
61	An interesting characteristic of GBM is its responsiveness to neurotransmitters, as
62	monoamines <sup>9-11</sup> . The well-known interplay between neurons and tumors, especially GBM
63	<sup>10,12</sup> , and the more recent identification of a synaptic neuron-GBM connectivity confirms that
64	neuron-secreted mediators are taken up by GBM cells, where they act as oncogenic stimuli
65	<sup>13</sup> . These findings paved the way for considering the addition of selected neuroleptic drugs
66	as potentially effective addition to GBM treatment <sup>14</sup> . Indeed, Many psychotherapeutic
67	drugs, act on several post-synaptic receptors and display polypharmacological activity <sup>14</sup> .

68	With these assumptions, we chose to evaluate the effects of one of the progenitors of
69	neuroleptic medications, i.e., the antipsychotic drug chlorpromazine (CPZ), in use for about
70	70 years for the therapy of several psychiatric disorders. CPZ is a compound listed in the
71	2021 WHO Model List of Essential Medicines <sup>15</sup> .
72	Delving into CPZ pharmacodynamics in vitro, our group assayed its effects on established
73	and primary human GBM cells. The results defined the role of this drug in hindering GBM cell
74	growth by acting at different levels through multimodal antitumor effects without any action
75	on non-cancer neuroepithelial cells <sup>16,17</sup> . In addition, CPZ acts synergistically with TMZ in
76	hindering GBM vitality and stemness capabilities <sup>16</sup> .
77	CPZ, besides not devoid of side effects, is a safe, low-cost and promptly available medication.
77 78	CPZ, besides not devoid of side effects, is a safe, low-cost and promptly available medication. All these conditions paved the way for repurposing CPZ as an add-on drug in GBM therapy.
77 78 79	CPZ, besides not devoid of side effects, is a safe, low-cost and promptly available medication. All these conditions paved the way for repurposing CPZ as an add-on drug in GBM therapy. To this end, we planned the RACTAC ( <u>Repurposing the Antipsychotic drug Ch</u> lorpromazine as
77 78 79 80	CPZ, besides not devoid of side effects, is a safe, low-cost and promptly available medication. All these conditions paved the way for repurposing CPZ as an add-on drug in GBM therapy. To this end, we planned the RACTAC ( <u>Repurposing the Antipsychotic drug Ch</u> lorpromazine as a <u>T</u> herapeutic <u>Agent in the <u>C</u>ombined treatment of newly diagnosed glioblastoma) Phase II</u>
77 78 79 80 81	CPZ, besides not devoid of side effects, is a safe, low-cost and promptly available medication. All these conditions paved the way for repurposing CPZ as an add-on drug in GBM therapy. To this end, we planned the RACTAC ( <u>Repurposing the Antipsychotic drug Ch</u> lorpromazine as a <u>T</u> herapeutic <u>Agent in the <u>C</u>ombined treatment of newly diagnosed glioblastoma) Phase II multicenter single arm study, in which CPZ is added to adjuvant TMZ in the first-line therapy</u>
77 78 79 80 81 82	CPZ, besides not devoid of side effects, is a safe, low-cost and promptly available medication. All these conditions paved the way for repurposing CPZ as an add-on drug in GBM therapy. To this end, we planned the RACTAC ( <u>Repurposing the Antipsychotic drug Ch</u> lorpromazine as a <u>T</u> herapeutic <u>Agent in the <u>C</u>ombined treatment of newly diagnosed glioblastoma) Phase II multicenter single arm study, in which CPZ is added to adjuvant TMZ in the first-line therapy of GBM patients whose tumor is characterized by an unmethylated <i>MGMT</i> gene promoter,</u>

#### **Patients and Methods** 85

#### Study design 86

87	This was a multicenter, prospective, single-arm clinical trial. The experimental procedure		
88	involved the combination of CPZ with standard treatment with TMZ in the adjuvant phase of		
89	the Stupp protocol <sup>2</sup> in newly diagnosed GBM patients carrying an unmethylated MGMT		
90	gene promoter. All patients received CPZ ("Largactil", from Teofarma S.R.L., Valle Salimbene		
91	(PV), Italy, as 25 mg tablets during the whole period of TMZ adjuvant treatment at a starting		
92	dose of 25 mg/day orally from day 1 of the TMZ adjuvant chemotherapy. The dosage was		
93	increased to 50 mg/day at the second cycle of treatment, if well tolerated, and continued for		
94	6 cycles or until disease progression, death, unacceptable toxicity, or consent withdrawal		
95	(Figure 1).		
96	This Phase II clinical trial has been approved by our Institutional Ethics Committee (Comitato		
97	Etico Centrale IRCCS - Sezione IFO-Fondazione Bietti, Rome, Italy) on September 6, 2019.		
98	The study is registered as EudraCT #2019-001988-75 and ClinicalTrials.gov Identifier		
99	#NCT0422444. All patients provided informed written consent prior to participating in any		
100	study procedures or treatments.		
101	Eligibility		
102	Patients aged 18-75 years with newly diagnosed and histologically confirmed supratentorial		

GBM (World Health Organization grade 4) and unmethylated *MGMT* gene promoter status 103 were eligible. Diagnosis of GBM was based on neurosurgical resection of the tumor or 104 105 biopsy. . Additional inclusion criteria were: age ≥18 years; gadolinium-enhanced MRI ,48 h 106 after surgery or before randomization; stable or decreasing dose of steroids for 1 week 107 before randomization; Karnowski performance status(KPS) >70; satisfactory laboratory blood

- and biochemical results within 2 weeks prior to randomization. Local assessment of O-6-
- 109 methylguanine-DNA methyltransferase (MGMT) methylation status on tumoral tissue was
- 110 required.
- 111 1.

#### 112 Endpoints

- 113 Progression-Free Survival (PFS) was the primary endpoint. PFS was defined as the time from
- the start of the Stupp regimen (radiotherapy plus concomitant TMZ) to the earliest
- 115 documented date of disease progression, based on Response Assessment in Neuro-Oncology
- (RANO) criteria <sup>18,19</sup>, as determined by the investigator, death due to any cause, or censored
- 117 at the date of the last assessment. Evaluating a meta-analysis performed on 91 GBM clinical
- trials, the choice of PFS as an endpoint can be considered appropriate as a surrogate
- 119 endpoint for earlier evaluation. The 6-mos PFS appears correlated with 1-year overall
- 120 survival (OS) and median OS <sup>20</sup>.
- 121 Secondary endpoints were as follows: (i)Overall survival (OS; defined as the time from
- diagnosis to the date of death from any cause or loss-to-follow-up; (ii) combination
- 123 treatment toxicity; adverse events (AEs) were evaluated according to the National Cancer
- 124 Institute's Common Terminology Criteria for Adverse Events version 5.0. Safety assessments
- 125 were performed from treatment initiation through 30 days after the last dose of
- 126 chemotherapy with TMZ plus CPZ; (iii) Quality of Life (QoL), assessed by means of the EORTC
- 127 QLQ C30+BN20 questionnaire at baseline and every 3 cycles <sup>21,22</sup>.

#### 128 Follow-up

129 Patients were followed-up monthly during adjuvant chemotherapy, and every 3 months.

130 after completion of the standard treatment if the disease was stable. Radiological

assessment was done by gadolinium (Gd) brain MRI every 12 weeks from the first drug
administration until disease progression.

Response assessment during study was based on investigators' evaluation using the RANO
 criteria <sup>18,19</sup>, which included blinded MRI readings, assessment of neurological status, KPS
 scores, and steroid use.

#### 136 Statistical analysis

- 137 All analyses were performed on the patients who received at least one dose of the study
- 138 treatment. The primary objective of the study was to evaluate the proportion of patients
- 139 free from progression after 6 months (PFS-6). Considering as unacceptable a percentage of
- 140 PFS-6 (P0) equal to 35% and a desirable PFS-6 of 55% (P1), a minimum of 41 patients would
- 141 be needed to guarantee a power of 80% at a significance level of 5% (one-sided), according
- to A'Hern <sup>23</sup>. If at least 20 patients were progression-free after 6 months, the treatment
- 143 would be considered sufficiently active. All survival curves were estimated by the Kaplan-
- 144 Meier method.
- 145 Clinical and demographic characteristics are reported as absolute counts and percentage
- 146 when related to categorical items and as median and range if referred to quantitative
- 147 variables.

#### 149 **Results**

#### 150 Patient characteristics

- 151 Between April 2020 and August 2022, 45 patients who met the eligibility requirements and
- 152 consented to participate were screened. Forty-one patients received at least one cycle of
- treatment and were included in the final analysis. Study follow-up was closed on December
- 154 31, 2022. Patients' baseline characteristics and demographics are summarized in **Table 1**.
- 155 Twenty patients (48,7%) completed 6 cycles of treatment with TMZ at standard dose plus
- 156 CPZ; twenty-one patients (51.2%) discontinued the treatment due to early progression
- 157 (mean cycles completed = 4.6). The median follow-up of was 15 months. (range 3–37).

#### 158 **Progression-free survival**

- 159 At 6 months, 27 patients were alive and without progression thus making possible the
- achievement of the primary endpoint. Overall, 35 patients (85.4%) underwent disease
- 161 progression, with a median PFS of 8.0 months. (95% CI: 7.0-9.0) (Figure 2A). PFS at different
- times is reported in **Table 2**.

#### 163 **Overall survival**

At the date of study closure, 29 deaths (69.7%) were observed, and median overall survival
has been 15.0 months (95% CI: 13.1-16.9). OS at different time-points is reported in Figure
2B and Table 2.

#### 167 **Toxicity**

168 . The RACTAC clinical experimentation has been correlated with the onset of an expected
169 dose-dependent sedation, especially at the beginning of the CPZ administration, and liver
170 toxicity (1 serious case), however expected for both CPZ and TMZ. Treatment was well
171 tolerated in all patients with mild somnolence (grade 1-2) in 8 (19,5%) and asthenia in 12

- 172 (29,2%) patients. In three patients, grade 3-4 hyper-transaminasaemia was observed (7%).
- 173 Adverse events lead to reduction or interruption of CPZ dosage in 4 patients (9,7%).
- 174 Decreased platelets count grade 3 was observed in one patient and neutropenia grade 3 in
- 175 one. All these data are summarized in **Table 3**.

## 177 Discussion

GBM patients with unmethylated MGMT promoter gene comprise 55-60% of total GBM 178 cases and present poorer prognosis due to an intrinsic resistance towards therapy with 179 alkylating agents. At present, while it is well recognized that TMZ brings a benefit in patients 180 181 with methylated *MGMT* gene promoter, it remains controversial whether this medication 182 should be administered or omitted when treating GBM patients with unmethylated MGMT gene promoter. Indeed, EANO evidence-based guidelines on diagnosis and treatment of 183 diffuse gliomas of adulthood report that TMZ might only be active in GBM patients with 184 methylated MGMT gene promoter, whereas its effectiveness on patients with unmethylated 185 MGMT gene promoter appears modest <sup>8,24</sup>. 186 Various therapeutic strategies have been investigated in several Phase II clinical trials, with 187 188 the aim to overcome drug resistance or to overpass DNA repair pathways in GBM patients with unmethylated *MGMT* gene promoter <sup>8,25</sup>. In the same setting, addition of drugs other 189 than TMZ alone did not lead to encouraging results <sup>26-28</sup>. Other studies evaluated the efficacy 190 191 of new agents in replacement of TMZ in the first line treatment of GBM patients with 192 unmethylated MGMT gene promoter. In the EORTC 26082 Phase II trial, temsirolimus was administered either during radiotherapy or as adjuvant treatment, showing no clinical 193 benefit <sup>29</sup>. In a single arm phase II trial, enzastaurin, a protein kinase C inhibitor, was 194 administered before, concomitantly with, and after radiotherapy to determine PFS-6 months 195 196 in GBM patients with unmethylated *MGMT* gene promoter, not achieving the primary endpoint <sup>30</sup>. On the other hand, in the same setting, therapy with bevacizumab plus 197 irinotecan provides a PFS at 6 months better than TMZ, but with no improvement in OS<sup>31</sup>. 198

Our results show that the addition of CPZ to standard TMZ in the first line treatment of GBM patients with unmethylated *MGMT* gene promoter was safe and led to a longer PFS than the one expected in this population of patients. A recent meta-analysis of pooled data from five Phase III clinical trials reported PFS and OS a in patients with unmethylated *MGMT* gene promoter of 4.99 and 14.11 months, respectively, when the standard-of-care GBM treatment was used <sup>32</sup>.

205 In our study, however, median OS was 15 months, thus not representing a clinically-relevant improvement with respect to data reported in this meta-analysis. Such an outcome could 206 207 also relate to the administration of CPZ only in the adjuvant phase of treatment. Further 208 studies are needed to test the concomitant association of CPZ also during radiotherapy. The safety profile of CPZ was consistent with its well-known pharmacological profile, even when 209 210 administered concomitantly with TMZ. In our study, the most frequent adverse event were mild somnolence (grade 1-2) in 18% of patients, usually in the first month of treatment, and 211 fatigue, observed in 30% of patients, a symptom commonly reported within a range of 40-212 213 70% in primary brain tumor patients<sup>33</sup>.

Quality of life (QoL) is an important outcome to be evaluated in these GBM patients. It has
been measured, as specified above, by means of the EORTC QLQ-C30 and QLQ-BN20
questionnaires. Presently, these evaluations are in progress and the results will be published
shortly.

218 Most relevant limitations of RACTAC trial are the small number of patients included in the 219 study and the lack of a control group. However, the clinical characteristics of patients at 220 baseline seem to be representative of the real-world population of MGMT unmethylated

221 GBM. PFS6 observed in this trial was 8 months and resulted promisingly longer than that

- 222 reported in previous published trials in this population.
- 223 Since the plasticity of GBM and its ability to remodulate its cell population based on the
- selective pressure generated by therapies, we can state that this tumor cannot be defined as
- a "single-path disease", being therefore very unsatisfying to treat it by means of targeted
- therapies. On these premises, it appears reasonable to consider the opportunity to use
- 227 "dirty drugs", i.e., drugs that are not too targeted, but are able to hit some generalized
- 228 vulnerabilities characterizing cancer cells.
- 229 CPZ is a well-known DRD2 antagonist <sup>34</sup> and therefore has been successfully used in the

treatment of psychiatric disorders. We intended to take advantage of its ability to interfere

with the function of DRD2, as well as a number of other neuromediator receptors

232 (https://go.drugbank.com/drugs/DB00477), to hamper the pseudo-synaptic, oncogenic

233 interplay between neurons and GBM.

Indeed, the results of the RACTAC clinical trial reported here can be considered at least as 234 proof-of-concept in supporting the effectiveness of interfering with the oncogenic 235 236 monoamine signaling between neurons and GBM. Of note, it should be considered that 237 there is also a profound interplay between peripheral/central nervous systems and cancer, 238 which acts through monoamine neuromediators and could represent a vulnerability targetable through the use of repurposed neuropsychiatric drugs in oncology and appliable 239 to diverse cancers <sup>35,36</sup>. Evaluating the features of CPZ possibly useful in GBM treatment, we 240 241 could also consider a number of studies showing the ability of this drug to hinder GBM malignant features in preclinical settings <sup>37</sup>. In the same context, during the course of the 242 RACTAC clinical trial, our group further refined the pharmacological effects of CPZ on GBM 243

244 cells in vitro, demonstrating the ability of this medication to hinder GBM malignant features at multiple levels <sup>16,17</sup> other than its known interference with the activity of 245 neurotransmitters. 246 Considering the escalation of the costs of novel anticancer medications, the long time it 247 takes for them to reach the market and the consequent nonavailability for a great number of 248 patients, the use of repurposed drugs can dramatically cut down time and drug expenses for 249 250 effective medications to reach the bedside, with significant benefits for the Health Systems. In addition, the characteristics inherent in repositionable drugs represent a further 251 therapeutic chance for GBM patients for which no second-line therapy is currently 252 253 established as effective or for those that have already experienced all known therapeutic opportunities. 254

255

### 256 Acknowledgments

Work partially financed by Funds Ricerca Corrente 2018-2019, 2020-2021, 2022-2023 from
Italian Ministry of Health (MGP) and by the European Union - NextGenerationEU through the
Italian Ministry of University and Research under PNRR - M4C2-I1.3 Project PE\_00000019
"HEAL ITALIA" to Marco G. Paggi, CUP H83C22000550006. The views and opinions expressed
are those of the authors only and do not necessarily reflect those of the European Union or
the European Commission. Neither the European Union nor the European Commission can
be held responsible for them.

This paper is dedicated to the memory of our friend and colleague Armando Felsani, who recently passed away and who contributed so much to the advancement of knowledge in the field of cell differentiation and cell cycle regulation.

- 267 Editorial and graphical assistance were provided by Aashni Shah, Valentina Attanasio and
- 268 Massimiliano Pianta (Polistudium SRL, Milan, Italy), and was supported by internal funds.

### 270 **References:**

- **1.** Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of
- Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016; 131(6):803-820.
- 273 2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant
- temozolomide for glioblastoma. *N Engl J Med.* 2005; 352(10):987-996.
- 275 3. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. *Nat Rev Cancer*.
  276 2003; 3(7):489-501.
- Lan X, Jorg DJ, Cavalli FMG, et al. Fate mapping of human glioblastoma reveals an invariant
   stem cell hierarchy. *Nature*. 2017; 549(7671):227-232.
- Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor
  hierarchy in a lethal cancer. *Genes Dev.* 2019; 33(11-12):591-609.
- 281 **6.** Couturier CP, Ayyadhury S, Le PU, et al. Single-cell RNA-seq reveals that glioblastoma
- recapitulates a normal neurodevelopmental hierarchy. *Nat Commun.* 2020; 11(1):3406.
- **7.** Hubert CG, Lathia JD. Seeing the GBM diversity spectrum. *Nat Cancer*. 2021; 2(2):135-137.
- **8.** Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide
- 285 in glioblastoma. *N Engl J Med.* 2005; 352(10):997-1003.
- 286 9. Caragher SP, Hall RR, Ahsan R, Ahmed AU. Monoamines in glioblastoma: complex biology
   287 with therapeutic potential. *Neuro Oncol.* 2018; 20(8):1014-1025.
- 288 10. Caragher SP, Shireman JM, Huang M, et al. Activation of Dopamine Receptor 2 Prompts
- 289 Transcriptomic and Metabolic Plasticity in Glioblastoma. *J Neurosci.* 2019; 39(11):1982-1993.
- 290 11. Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells
- drives brain tumour progression. *Nature*. 2019; 573(7775):532-538.
- **12.** Barygin OI, Nagaeva EI, Tikhonov DB, Belinskaya DA, Vanchakova NP, Shestakova NN.
- 293 Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics.
- 294 Brain Res. 2017; 1660:58-66.

- **13.** Venkataramani V, Schneider M, Giordano FA, et al. Disconnecting multicellular networks in
- brain tumours. *Nat Rev Cancer.* 2022.
- **14.** Persico M, Abbruzzese C, Matteoni S, et al. Tackling the Behavior of Cancer Cells: Molecular
- 298 Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma. *Cells.* 2022;
- 299 11(2):263.
- World Health Organization Model List of Essential Medicines, 22nd List. Geneva: World
   Health Organization; 2021.
- 302 16. Matteoni S, Matarrese P, Ascione B, et al. Anticancer Properties of the Antipsychotic Drug
- 303 Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma
- 304 Proliferation In Vitro. *Front Oncol.* 2021; 11:635472.
- **17.** Matteoni S, Matarrese P, Ascione B, et al. Chlorpromazine induces cytotoxic autophagy in
- 306 glioblastoma cells via endoplasmic reticulum stress and unfolded protein response. *J Exp Clin* 307 *Cancer Res.* 2021; 40(1):347.
- **18.** Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-
- 309 grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol.* 2010;
- 310 28(11):1963-1972.
- **19.** Radbruch A, Fladt J, Kickingereder P, et al. Pseudoprogression in patients with glioblastoma:
   clinical relevance despite low incidence. *Neuro Oncol.* 2015; 17(1):151-159.
- **20.** Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall
- survival in glioblastoma: a literature-based meta-analysis from 91 trials. *Neuro Oncol.* 2014;
  16(5):696-706.
- 316 **21.** Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and
- 317 Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical
- 318 trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-376.

319	22.	Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a	
320		brain cancer quality-of-life questionnaire for use in combination with general cancer-specific	
321		questionnaires. Qual Life Res. 1996; 5(1):139-150.	
322	23.	A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;	
323		20(6):859-866.	
324	24.	Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and	
325		treatment of diffuse gliomas of adulthood. <i>Nat Rev Clin Oncol.</i> 2021; 18(3):170-186.	
326	25.	Weiler M, Hartmann C, Wiewrodt D, et al. Chemoradiotherapy of newly diagnosed	
327		glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010; 77(3):670-	
328		676.	
329	26.	Nabors LB, Fink KL, Mikkelsen T, et al. Two cilengitide regimens in combination with standard	
330		treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene	
331		promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro	
332		<i>Oncol.</i> 2015; 17(5):708-717.	
333	27.	Raizer JJ, Giglio P, Hu J, et al. A phase II study of bevacizumab and erlotinib after radiation	
334		and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 2016; 126(1):185-	
335		192.	
336	28.	Asano K, Fumoto T, Matsuzaka M, et al. Combination chemoradiotherapy with	
337		temozolomide, vincristine, and interferon-beta might improve outcomes regardless of O6-	
338		methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly	
339		glioblastoma. BMC cancer. 2021; 21(1):867.	
340	29.	Wick W, Gorlia T, Bady P, et al. Phase II Study of Radiotherapy and Temsirolimus versus	
341		Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma	
342		without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res. 2016;	
343		22(19):4797-4806.	

Wick W, Steinbach JP, Platten M, et al. Enzastaurin before and concomitant with radiation

345		therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed
346		glioblastoma without MGMT promoter hypermethylation. Neuro Oncol. 2013; 15(10):1405-
347		1412.
348	31.	Herrlinger U, Schafer N, Steinbach JP, et al. Bevacizumab Plus Irinotecan Versus
349		Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase
350		Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. 2016;
351		34(14):1611-1619.
352	32.	Alnahhas I, Alsawas M, Rayi A, et al. Characterizing benefit from temozolomide in MGMT
353		promoter unmethylated and methylated glioblastoma: a systematic review and meta-
354		analysis. Neurooncol Adv. 2020; 2(1):vdaa082.
355	33.	Valko PO, Siddique A, Linsenmeier C, Zaugg K, Held U, Hofer S. Prevalence and predictors of
356		fatigue in glioblastoma: a prospective study. Neuro Oncol. 2015; 17(2):274-281.
357	34.	Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine
358		receptors. <i>Pharmacol Rev.</i> 2011; 63(1):182-217.
359	35.	Magnon C, Hondermarck H. The neural addiction of cancer. Nat Rev Cancer. 2023.
360	36.	Chang A, Botteri E, Gillis RD, et al. Beta-blockade enhances anthracycline control of
361		metastasis in triple-negative breast cancer. Sci Transl Med. 2023; 15(693):eadf1147.
362	37.	Abbruzzese C, Matteoni S, Persico M, Villani V, Paggi MG. Repurposing chlorpromazine in the
363		treatment of glioblastoma multiforme: analysis of literature and forthcoming steps. J Exp Clin
364		Cancer Res. 2020; 39(1):26.
365 366		
367		

368

344

30.

369

# Figure 1



371 Scheme of the daily addition for of CPZ during the adjuvant phase of the first line protocol

372 for newly diagnosed GBM patients.

Figure 2



376

375

377 Kaplan-Meier curves describing PFS and OS trends in GBM patients with unmethylated

378 *MGMT* gene promoter treated according to the RACTAC protocol.

## 380

#### 381

# Table 1

## Baseline characteristics of the enrolled GBM patients

382

	Baseline characteristics
Variables	Study population (n= 41)
Age at diagnosis	
(Median, y)	56 (range 20-75)
Gender	M 29 (70.7%)
KPS median	90 (range 70-100)
Extent of resection %	GTR 41.5; Partial 56.1; Biopsy 2.4
Steroid treatment at baseline # (%)	21 (51%)
Dexamethasone dose (mean)	4 mg

383

## 384 KPS=Karnofsky Performance status; GTR=Gross Total resection

#### 386

## Table 2

# 387 Progression-free survival (PFS) and overall survival (OS) in GBM patients with unmethylated

388 *MGMT* gene promoter treated according to the RACTAC protocol.

	6 months	12 months	18 months	24 months
PFS	68.3%	24.4%	12.4%	12.4%
OS	95.1%	72.0%	38.9%	25.5%

389

### 391

## Table 3

#### 392

## Drug-related adverse events

Adverse events	Grade 1-2	Grade >2
Somnolence	8	-
Fatigue	11	1
Hypertransaminasemia	1	2
Thrombocytopenia	6	1
Neutropenia	1	1